282 related articles for article (PubMed ID: 27854302)
21. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population.
Tassaneeyakul W; Jantararoungtong T; Chen P; Lin PY; Tiamkao S; Khunarkornsiri U; Chucherd P; Konyoung P; Vannaprasaht S; Choonhakarn C; Pisuttimarn P; Sangviroon A; Tassaneeyakul W
Pharmacogenet Genomics; 2009 Sep; 19(9):704-9. PubMed ID: 19696695
[TBL] [Abstract][Full Text] [Related]
22. Genetic basis for idiosyncratic reactions to antiepileptic drugs.
Franciotta D; Kwan P; Perucca E
Curr Opin Neurol; 2009 Apr; 22(2):144-9. PubMed ID: 19262378
[TBL] [Abstract][Full Text] [Related]
23. Pharmacogenetics of hypersensitivity drug reactions.
Negrini S; Becquemont L
Therapie; 2017 Apr; 72(2):231-243. PubMed ID: 28162244
[TBL] [Abstract][Full Text] [Related]
24. Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study.
Ko TM; Tsai CY; Chen SY; Chen KS; Yu KH; Chu CS; Huang CM; Wang CR; Weng CT; Yu CL; Hsieh SC; Tsai JC; Lai WT; Tsai WC; Yin GD; Ou TT; Cheng KH; Yen JH; Liou TL; Lin TH; Chen DY; Hsiao PJ; Weng MY; Chen YM; Chen CH; Liu MF; Yen HW; Lee JJ; Kuo MC; Wu CC; Hung SY; Luo SF; Yang YH; Chuang HP; Chou YC; Liao HT; Wang CW; Huang CL; Chang CS; Lee MT; Chen P; Wong CS; Chen CH; Wu JY; Chen YT; Shen CY;
BMJ; 2015 Sep; 351():h4848. PubMed ID: 26399967
[TBL] [Abstract][Full Text] [Related]
25. Clinical application of pharmacogenomics: the example of HLA-based drug-induced toxicity.
Lee MT; Mahasirimongkol S; Zhang Y; Suwankesawong W; Chaikledkaew U; Pavlidis C; Patrinos GP; Chantratita W
Public Health Genomics; 2014; 17(5-6):248-55. PubMed ID: 25341524
[TBL] [Abstract][Full Text] [Related]
26. Stevens-Johnson Syndrome in an Adult Filipino Male Positive for HLA-B*38:16 and B*58:17, Associated With Allopurinol: A Case Report.
Reyes-Ramos AR; Preclaro IAC; Castillo MMS; Basco SES
J Clin Pharmacol; 2023 Jun; 63(6):742-744. PubMed ID: 36790080
[No Abstract] [Full Text] [Related]
27. Evolving models of the immunopathogenesis of T cell-mediated drug allergy: The role of host, pathogens, and drug response.
White KD; Chung WH; Hung SI; Mallal S; Phillips EJ
J Allergy Clin Immunol; 2015 Aug; 136(2):219-34; quiz 235. PubMed ID: 26254049
[TBL] [Abstract][Full Text] [Related]
28. HLA-B*58:01 strongly associates with allopurinol-induced adverse drug reactions in a Japanese sample population.
Niihara H; Kaneko S; Ito T; Sugamori T; Takahashi N; Kohno K; Morita E
J Dermatol Sci; 2013 Aug; 71(2):150-2. PubMed ID: 23669020
[No Abstract] [Full Text] [Related]
29. Genetic markers of severe cutaneous adverse reactions.
Jung JW; Kim JY; Park IW; Choi BW; Kang HR
Korean J Intern Med; 2018 Sep; 33(5):867-875. PubMed ID: 29921043
[TBL] [Abstract][Full Text] [Related]
30. Pharmacogenetics of drug hypersensitivity.
Phillips EJ; Mallal SA
Pharmacogenomics; 2010 Jul; 11(7):973-87. PubMed ID: 20602616
[TBL] [Abstract][Full Text] [Related]
31. Pharmacogenomic Advances in the Prediction and Prevention of Cutaneous Idiosyncratic Drug Reactions.
Pan RY; Dao RL; Hung SI; Chung WH
Clin Pharmacol Ther; 2017 Jul; 102(1):86-97. PubMed ID: 28295240
[TBL] [Abstract][Full Text] [Related]
32. HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population.
Gonçalo M; Coutinho I; Teixeira V; Gameiro AR; Brites MM; Nunes R; Martinho A
Br J Dermatol; 2013 Sep; 169(3):660-5. PubMed ID: 23600531
[TBL] [Abstract][Full Text] [Related]
33. Pharmacogenetic Testing for Prevention of Severe Cutaneous Adverse Drug Reactions.
Chang CJ; Chen CB; Hung SI; Ji C; Chung WH
Front Pharmacol; 2020; 11():969. PubMed ID: 32714190
[TBL] [Abstract][Full Text] [Related]
34. Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland.
Wang Q; Zhou JQ; Zhou LM; Chen ZY; Fang ZY; Chen SD; Yang LB; Cai XD; Dai QL; Hong H; Wang HX
Seizure; 2011 Jul; 20(6):446-8. PubMed ID: 21397523
[TBL] [Abstract][Full Text] [Related]
35. Tailoring of recommendations to reduce serious cutaneous adverse drug reactions: a pharmacogenomics approach.
Tan-Koi WC; Sung C; Chong YY; Lateef A; Pang SM; Vasudevan A; Aw D; Lui NL; Lee SX; Ren EC; Koay ES; Tay YK; Lim YL; Lee HY; Dong D; Loke C; Tan L; Limenta M; Lee EJ; Toh D; Chan CL
Pharmacogenomics; 2017 Jun; 18(9):881-890. PubMed ID: 28594314
[TBL] [Abstract][Full Text] [Related]
36. Pharmacogenetics of toxic epidermal necrolysis.
Lee MT; Hung SI; Wei CY; Chen YT
Expert Opin Pharmacother; 2010 Sep; 11(13):2153-62. PubMed ID: 20536296
[TBL] [Abstract][Full Text] [Related]
37. Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosis.
Chung WH; Hung SI
J Dermatol Sci; 2012 Jun; 66(3):190-6. PubMed ID: 22541332
[TBL] [Abstract][Full Text] [Related]
38. Stevens-Johnson syndrome and toxic epidermal necrolysis: an update on pharmacogenetics studies in drug-induced severe skin reaction.
Rufini S; Ciccacci C; Politi C; Giardina E; Novelli G; Borgiani P
Pharmacogenomics; 2015 Nov; 16(17):1989-2002. PubMed ID: 26555663
[TBL] [Abstract][Full Text] [Related]
39. Comparison between the
Saksit N; Nakkam N; Konyoung P; Khunarkornsiri U; Tassaneeyakul W; Chumworathayi P; Kanjanawart S; Sukasem C; Sangviroon A; Pattanacheewapull O; Tassaneeyakul W
J Immunol Res; 2017; 2017():2738784. PubMed ID: 29392141
[TBL] [Abstract][Full Text] [Related]
40. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions.
Chung WH; Chang WC; Lee YS; Wu YY; Yang CH; Ho HC; Chen MJ; Lin JY; Hui RC; Ho JC; Wu WM; Chen TJ; Wu T; Wu YR; Hsih MS; Tu PH; Chang CN; Hsu CN; Wu TL; Choon SE; Hsu CK; Chen DY; Liu CS; Lin CY; Kaniwa N; Saito Y; Takahashi Y; Nakamura R; Azukizawa H; Shi Y; Wang TH; Chuang SS; Tsai SF; Chang CJ; Chang YS; Hung SI; ;
JAMA; 2014 Aug; 312(5):525-34. PubMed ID: 25096692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
